Literature DB >> 23930231

A case of amelioration of venlafaxine-discontinuation "brain shivers" with atomoxetine.

Jose A Cortes1, Rajiv Radhakrishnan.   

Abstract

Entities:  

Year:  2013        PMID： 23930231      PMCID： PMC3733524          DOI： 10.4088/PCC.12l01427

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  12 in total

1.  Shock-like sensations during venlafaxine withdrawal.

Authors:  Roy R Reeves; James E Mack; John J Beddingfield
Journal:  Pharmacotherapy       Date:  2003-05       Impact factor: 4.705

2.  Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.

Authors:  M Fava; R Mulroy; J Alpert; A A Nierenberg; J F Rosenbaum
Journal:  Am J Psychiatry       Date:  1997-12       Impact factor: 18.112

3.  The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("ecstasy") in humans.

Authors:  C M Hysek; L D Simmler; M Ineichen; E Grouzmann; M C Hoener; R Brenneisen; J Huwyler; M E Liechti
Journal:  Clin Pharmacol Ther       Date:  2011-06-15       Impact factor: 6.875

Review 4.  Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research.

Authors:  Alan F Schatzberg; Pierre Blier; Pedro L Delgado; Maurizio Fava; Peter M Haddad; Richard C Shelton
Journal:  J Clin Psychiatry       Date:  2006       Impact factor: 4.384

5.  A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters.

Authors:  Georgianna G Gould; Alfonso V Altamirano; Martin A Javors; Alan Frazer
Journal:  Biol Psychiatry       Date:  2005-09-02       Impact factor: 13.382

6.  Serotonin reuptake inhibitor withdrawal.

Authors:  N J Coupland; C J Bell; J P Potokar
Journal:  J Clin Psychopharmacol       Date:  1996-10       Impact factor: 3.153

7.  Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Authors:  Frank P Bymaster; Jason S Katner; David L Nelson; Susan K Hemrick-Luecke; Penny G Threlkeld; John H Heiligenstein; S Michelle Morin; Donald R Gehlert; Kenneth W Perry
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

8.  Ex vivo assessment of binding site occupancy of monoamine reuptake inhibitors: methodology and biological significance.

Authors:  Kelly Lengyel; Rick Pieschl; Todd Strong; Thaddeus Molski; Gail Mattson; Nicholas J Lodge; Yu-Wen Li
Journal:  Neuropharmacology       Date:  2008-04-25       Impact factor: 5.250

9.  Lhermitte's sign, electric shock sensations and high dose ecstasy consumption: preliminary findings.

Authors:  B Boland; L Mitcheson; K Wolff
Journal:  J Psychopharmacol       Date:  2009-02-24       Impact factor: 4.153

10.  Effects of venlafaxine on extracellular 5-HT, dopamine and noradrenaline in the hippocampus and on peripheral hormone concentrations in the rat in vivo.

Authors:  M F Piacentini; R Clinckers; R Meeusen; S Sarre; G Ebinger; Y Michotte
Journal:  Life Sci       Date:  2003-09-26       Impact factor: 5.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.